Publications:

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.

Nature Medicine

Johnson, Neil N; Li, Yu-Chen YC; Walton, Zandra E ZE; Cheng, Katherine A KA; Li, Danan D; Rodig, Scott J SJ; Moreau, Lisa A LA; Unitt, Christine C; Bronson, Roderick T RT; Thomas, Huw D HD; Newell, David R DR; D'Andrea, Alan D AD; Curtin, Nicola J NJ; Wong, Kwok-Kin KK; Shapiro, Geoffrey I GI

Publication Date: 2011-06-26

Variant appearance in text: BRCA1: S1189A

PubMed Link: 21706030

Variant Present in the following documents:

• Main text
• nihms288730.pdf

View BVdb publication page

Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage.

Molecular Cell

Johnson, Neil N; Cai, Dongpo D; Kennedy, Richard D RD; Pathania, Shailja S; Arora, Mansi M; Li, Yu-Chen YC; D'Andrea, Alan D AD; Parvin, Jeffrey D JD; Shapiro, Geoffrey I GI

Publication Date: 2009-08-14

Variant appearance in text: BRCA1: S1189A

PubMed Link: 19683496

Variant Present in the following documents:

• Main text

View BVdb publication page